Roche projects mid-single digit group sales growth in 2025, with core EPS growth in the high-single digit range. The company expects a CHF1.2 billion impact from the loss of exclusivity but aims to ...

After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year on the market. | After repeatedly wowing investors, Roche’s star eye med ...

When Pamela Hobbs started to suffer memory loss and became clumsy, she thought it was the menopause, but it turned out to be a stroke.

Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%.

The biosimilar's safety and immunogenicity profiles were found to be comparable to those of the reference product in the ...

EMA accepts for review regulatory application of GSK’s Shingrix new prefilled syringe presentation for prevention of shingles: London, UK Wednesday, January 29, 2025, 13:00 Hrs ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...

The syringe filling machine industry is experiencing significant growth due to the increasing demand for injectable medications, particularly with the rise of biologics, vaccines, and precision ...

The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the regulatory application of a prefilled syringe ...

This European review of the prefilled syringe follows GSK's receipt of approval from the US Food & Drug Administration on January 8. GSK is also investigating submission of the new presentation to ...